{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-009109","form_type":"8-K","ticker":"MRK","cik":"0000310158","company_name":"Merck & Co., Inc.","filed_at":"2024-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.532966+00:00","generated_at":"2026-06-06T11:44:26.787801+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Merck reports Q4 GAAP loss of $0.48/share; plans $4B restructuring; FY2024 EPS guidance $8.44-8.59","bullets":["Q4 2023 GAAP net loss $1.2B ($0.48 loss per share); non-GAAP EPS $0.03, includes $1.69/share Daiichi Sankyo charge.","Full-year 2023 sales $60.1B (+1% YoY); KEYTRUDA $25B (+19%), GARDASIL $8.9B (+29%), LAGEVRIO down 75% to $1.4B.","FY 2024 outlook: sales $62.7-64.2B; non-GAAP EPS $8.44-8.59.","Approved 2024 Restructuring Program with cumulative pretax costs ~$4B; ~60% non-cash; substantially complete by end of 2031."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-009109","json":"https://secwatch.observer/filing/0001104659-24-009109.json","markdown":"https://secwatch.observer/filing/0001104659-24-009109.md","text":"https://secwatch.observer/filing/0001104659-24-009109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/tm244517d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T11:44:26.787801+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"de3cd628342b617b3a176c876d2c6f54e5f88f81","claim":"Merck & Co., Inc. reported fourth quarter and full year of 2023 results: revenue $14.6 billion.","evidence_excerpt":"Merck Announces Fourth-Quarter and Full-Year 2023 Financial Results - Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines - Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year of 2023"},{"label":"Revenue","value":"$14.6 billion"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"de4b55bc0703a0455722aa5aedbdf3a92061efcb","claim":"Merck & Co., Inc. announced a restructuring with charges of approximately $4.0 billion affecting the Company's Human Health global manufacturing network … and also optimize the Animal Health global manufacturing network.","evidence_excerpt":"expected to be substantially completed by the end of 2031, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $4.0 billion. Approximately 60% of the $4.0 billion will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested; the remainder of the costs","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/310158/000110465924009109/0001104659-24-009109-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $4.0 billion"},{"label":"Affected area","value":"the Company's Human Health global manufacturing network … and also optimize the Animal Health global manufacturing network"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}